RE
TSHA icon

RBC Europe’s Taysha Gene Therapies TSHA Stock Holding History

RBC Europe’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250
Closed -$4.66K – 1115
2021
Q3 		$4.66K Hold
250
– – ﹤0.01% 1053
2021
Q2 		$5.3K Hold
250
– – ﹤0.01% 1042
2021
Q1 		$5.08K Hold
250
– – ﹤0.01% 1002
2020
Q4 		$6.63K Buy
+250
New +$5.39K ﹤0.01% 936

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

RBC Europe's TSHA Position: Q4 2021 in Review

RBC Europe sold out of Taysha Gene Therapies (TSHA) in Q4 2021, closing a stake of 250 shares — an estimated $4.66K sold.

RBC Europe first reported a position in TSHA in Q4 2020 and held it in 4 quarters. The position peaked at $6.63K in Q4 2020. 65 funds tracked by Wall St. Rank hold TSHA as of Q4 2021.

  • RBC Europe reported no remaining Taysha Gene Therapies position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 250 Taysha Gene Therapies shares in Q4 2021, an estimated $4.66K.
  • RBC Europe first reported a position in Taysha Gene Therapies in Q4 2020 and held it in 4 quarters.
  • RBC Europe's Taysha Gene Therapies position peaked at $6.63K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.